Novocure (NVCR) Announces FDA Approval of Optune Combo as Newly Diagnosed GBM Treatment
Tweet Send to a Friend
Novocure (NASDAQ: NVCR) announced that the U.S. Food and Drug Administration (FDA) has approved Optune in combination with temozolomide for ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
